Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2025-10-10

FDA Approved: LAMICTAL ODT — Supplemental Application (GlaxoSmithKline LLC)

View source ↗

Summary

FDA approved a supplemental application for Lamictal ODT (lamotrigine) from GlaxoSmithKline, likely updating labeling to reflect the orally disintegrating table…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LAMICTAL ODT (lamotrigine)

Snippet

SUPPL AP for LAMICTAL ODT (LAMOTRIGINE)